Nobel Prize Winner Presents Findings on Hormone Therapy for Treating Prostate Cancer
Andrew V. Schally, Ph.D., M.D.h.c., D. Sc.h.c., the 1977 Nobel Prize winner for physiology or medicine, Distinguished Medical Research Scientist of the Department of Veterans Affairs, professor in the Department of Pathology at the Miller School of Medicine and professor in the Division of Hematology-Oncology at UM/Sylvester Comprehensive Cancer Center, presented a lecture in Vienna to the World Congress on Men’s Health & Gender on September 22. His focus was on the future of hormone therapy in treating prostate cancer.
Dr. Schally and his team are investigating the use of Growth Hormone-Releasing Hormone (GH-RH) antagonists and cytotoxic analogs of Luteinising Hormone-Releasing Hormone (LH-RH), one of which is AN-152.
In experiments with castrated nude mice bearing xenografted human prostate cancers, Dr. Schally, a leader in the study of hormone-related cancers, discovered that the cytotoxic analog AN-152 was effective at inhibiting tumor growth. He says AN-152 should be effective in patients with prostate cancer who relapsed following androgen deprivation therapy. “Hopefully, AN-152 should enter into clinical trials within six months or so,” said Dr. Schally. He anticipates another two or three years of experimental work on the development of GH-RH antagonists before this new class of antitumor compound reaches the clinical phase.
Earlier this year, Dr. Schally identified a protein receptor that stimulates growth in a variety of cancers.